Objective：To investigate the efficacy and safety of zoledronic acid combined with taxotere in treatment of breast cancer patients with multiple bone metastases and negative hormone receptors.
Methods：Thirty-six breast cancer patients with multiple bone metastases were randomized devided into two groups: Group A(zoledronic acid plus taxotere) and Group B(zoledronic acid alone).The effect in the two groups was compared.
Results：Relief of bone pain, improvement in quality of life, and toxic side effects between the two groups showed no significant difference. The effect on bone metastases was 66.7%（12/18）in group A, which was significantly higher than that in group B(11.1%,2/18) (P＜0.05).
Conclusions：Zoledronic acid combined with taxotere for breast cancer patients with bone metastases has favorable therapeatic efficacy.